

AMENDMENTS TO THE CLAIMS:

1. (Currently amended) A method of treating a neoplastic disease in a subject, the method comprising:

administering to a subject having a tumor a pharmaceutically acceptable salt of an inorganic selenium-containing compound (iSe compound) in an amount effective to alter a reduction-oxidation state of a tumor cell toward oxidation; and

administering ~~a cancer~~ radiation therapy ~~other than an iSe compound~~ to the subject; wherein the neoplastic disease in the subject is treated.

2. (Original) The method of claim 1, wherein the iSe compound is inorganic selenite.

3. (Currently amended) The method of claim 1, wherein the ~~cancer~~-radiation therapy is administered after administering the iSe compound.

4. (Original) The method of claim 1, wherein the neoplastic disease is prostate cancer.

5. (Cancelled)

6. (Currently amended) The method of claim ~~[[5]]~~ 1, wherein the radiation therapy is external beam radiation therapy, brachytherapy or systemically targeted radiation.

7. (Cancelled)

8. (Original) The method of claim 1, wherein said administering of the iSe compound is intravenous, tumor targeted, intratumoral, or peritumoral.

9. (Currently amended) The method of claim 1, wherein the iSe compound is administered for a time sufficient for metabolism of the iSe compound prior to administering the radiation cancer-therapy.

10. (Currently amended) A method of enhancing sensitivity of a tumor in a subject to ~~a cancer-radiation~~ therapy, the method comprising:
administering to a subject having a tumor a pharmaceutically acceptable salt of an inorganic selenium-containing (iSe) compound in an amount effective to sensitize the tumor to ~~a cancer-radiation~~ therapy; and
administering the ~~cancer~~ radiation therapy to the subject;
wherein administration of the iSe compound is effective to enhance sensitivity of the tumor to the ~~cancer~~-radiation therapy.

11. (Original) The method of claim 10, wherein inorganic selenium-containing compound is inorganic selenite.

12-14. (Cancelled)

15. (Currently amended) A method of treating prostate cancer, the method comprising:
administering to a subject having prostate cancer a pharmaceutically acceptable salt of an inorganic selenite; and
administering ~~a cancer- radiation~~ therapy ~~other than inorganic selenite~~ to the subject;
wherein administering the inorganic selenite and the ~~cancer-radiation~~ therapy provides for a synergistic effect in prostate cancer cell growth inhibition to treat the prostate cancer.

16-18. (Cancelled)